Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.75 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.75 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.75 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.75 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.75 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.75 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.75 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.67 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.67 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14516209 | 1.00 | OPRM1 (0.75) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| Hydrochloric Acid SCHEMBL6848238 | 0.99 | OPRM1 (0.74) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL2351367 | 0.91 | OPRD1 (0.73) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL28786036 | 0.91 | OPRD1 (0.69) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL8978975 | 0.90 | OPRM1 (0.70) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL15757784 | 0.89 | OPRD1 (0.80) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL24971 | 0.89 | OPRD1 (0.80) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL14516212 | 0.89 | OPRD1 (0.80) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL31058362 | 0.89 | OPRD1 (0.80) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL14611951 | 0.89 | OPRD1 (0.80) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110612119-A | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | 西雅图儿童医院（DBA西雅图儿童研究所） | 2019-12-24 | — | — | CN | claimed |
| WO-2018148224-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2018-08-16 | — | — | WO | claimed |
| CN-101203250-B | Methods and compositions for the delivery of biologically active agents via non-covalent interaction, and formed articles | INTERFACE BIOLOGICS INC | 2013-03-20 | — | — | CN | claimed |
| CN-101203250-A | Methods and compositions for the delivery of biologically active agents | INTERFACE BIOLOGICS INC (CA) | 2008-06-18 | — | — | CN | claimed |
| EP-1767221-A2 | PREPARATION AND USE OF A BIVALENT VACCINE AGAINST MORPHINE-HEROINE ADDICTION | INSTITUTO NACIONAL DE PSIQUIATRIA RAMON DE LA FUENTE MUNIZ (MX) | 2007-03-28 | — | — | EP | claimed |
| US-20070037891-A1 | Methods and compositions for the delivery of biologically active agents | INTERFACE BIOLOGICS (CA) | 2007-02-15 | — | — | US | claimed |
| EP-1423392-B1 | DERIVATIVES OF MORPHINE-LIKE OPIOID COMPOUNDS | NEURO THERAPEUTICS LTD (AU) | 2006-10-04 | — | — | EP | claimed |
| US-20060111381-A1 | Amidine compounds | MONASH UNIVERSITY (AU) | 2006-05-25 | — | — | US | claimed |
| EP-1053238-B1 | THERAPEUTIC COMPOUNDS | UNIV MONASH (AU) | 2005-12-28 | — | — | EP | claimed |
| US-20040242616-A1 | Derivatives of morphine-like opioid compounds | NEURO THERAPEUTICS LIMITED (AU) | 2004-12-02 | — | — | US | claimed |
| US-6784186-B1 | OPIODS WHICH HAVE LESS ACTIVITY WITHIN THE CENTRAL NERVOUS SYSTEM, THUS HAVING FEWER UNDESIRABLE SIDE-EFFECTS | MONASH UNIVERSITY (AU) | 2004-08-31 | — | — | US | claimed |
| EP-1053238-A4 | THERAPEUTIC COMPOUNDS | UNIV MONASH (AU) | 2003-09-03 | — | — | EP | claimed |
| EP-1053238-A1 | THERAPEUTIC COMPOUNDS | MONASH UNIVERSITY (AU) | 2000-11-22 | — | — | EP | claimed |
| WO-1999038869-A1 | THERAPEUTIC COMPOUNDS | MONASH UNIVERSITY (AU) | 1999-08-05 | — | — | WO | claimed |
| CN-110612119-B | Phosphatidylether (PLE) CAR T cell tumor targeting (CTCT) agents | 西雅图儿童医院（DBA西雅图儿童研究所） | 2024-10-29 | — | — | CN | disclosed |
| US-20240226160-A9 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240131072-A1 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-04-25 | — | — | US | disclosed |
| EP-0635019-A1 | NOVEL OPIATE DERIVATIVES AND PROTEIN AND POLYPEPTIDE OPIATE DERIVATIVE CONJUGATES AND LABELS | BIOSITE DIAGNOSTICS INC. (US) | 1995-01-25 | — | — | EP | disclosed |
| EP-0579767-A1 | NOVEL CONJUGATES AND ASSAYS FOR SIMULTANEOUS DETECTION OF MULTIPLE LIGANDS | BIOSITE DIAGNOSTICS INC. (US) | 1994-01-26 | — | — | EP | disclosed |
| WO-1992018866-A1 | NOVEL CONJUGATES AND ASSAYS FOR SIMULTANEOUS DETECTION OF MULTIPLE LIGANDS | BIOSITE DIAGNOSTICS INCORPORATED (US) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111381-A1 | Amidine compounds | OPRM1, OPRD1, OPRK1 | OPRM1 1/4885OPRD1 2/4885OPRK1 3/4885 |
| US-20040242616-A1 | Derivatives of morphine-like opioid compounds | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.